Tonix Pharmaceuticals Holding Corp. (TNXP)
TNXPNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$4.68
+0.1300 (+2.86%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $77.01m
- P/E
- –
- EPS, last 4 quarters
- $-12.94
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.55 to $20.56
- Average volume
- 713.6k
- Previous close
- $4.55
Analysts
4 coveringStrong Buy4 buy, 0 hold, 0 sell
Targets a year out average $23.50, +402.1% from here
Earnings
next estimate $-2.51Next report
Sep 2025
0.0%
Dec 2025
-25.9%
Mar 2026
-23.1%
Jun 2026
+10.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $3.29m | $5.39m | $6.88m | $13.54m |
| Gross profit | $1.92m | $4.33m | $5.30m | $12.84m |
| Operating income | -$33.07m | -$48.29m | -$41.54m | -$42.53m |
| Net income | -$32.01m | -$46.91m | -$40.19m | -$40.55m |
Last four quarters: revenue $29.10m, margin -548.6%, free cash flow -$158.11m
News
8 latest- Tonix Pharmaceuticals (TNXP) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 hours ago
- Tonix Pharmaceuticals Holding Corp. Reports Third Quarter 2026 Financial ResultsFintel · 9 hours ago
- Tonix Q3 Loss Widens On Higher Costs, Tonmya Sales Rise From Q2; Shares Fall 18% Premarket RTTNews · 12 hours ago
- Canaccord Genuity Initiates Coverage of Tonix Pharmaceuticals Holding with BuyFintel · Oct 26, 2026
- Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine Candidate RTTNews · Oct 15, 2026
- Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial NearsMarketBeat · Sep 11, 2026
- Tonix Names Englese Chief Commercial Officer To Expand TONMYA Reach RTTNews · Sep 8, 2026
- Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression PipelineMarketBeat · Aug 18, 2026
The company
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company's flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute stress reaction.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- tonixpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.